Advertisement

Topics

New heart attack data boost AZ’s Brilinta

07:54 EDT 24 Aug 2017 | pharmaphorum

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European Society of Cardiology meeting in Barcelona, and is a...

Original Article: New heart attack data boost AZ’s Brilinta

NEXT ARTICLE

More From BioPortfolio on "New heart attack data boost AZ’s Brilinta"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...